Impact of Nutritional Management on the Frailty of Patients Waiting for Liver Transplantation (Via the LFI Tool)
- Sponsor
- Hospices Civils de Lyon
- Study ID
- NCT06911619
- Status
- Recruiting
Conditions
- Cirrhosis
- Fragility
- Hepatic Transplantation
- Undernutrition
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dietary management — DIETARY_SUPPLEMENTThe intervention consists of a personalized dietary management with a nutritional follow-up pending transplantation. Teleconsultation appointments are scheduled with the dietician for dietary coaching and a re-evaluation of the nutritional strategy every month. Follow-up visits in person, carried out by the dietitian at the 3rd and 6th month waiting for transplant and are coupled with the usual consultations with the referring hepatologist. The visits allow the realization of LFI (Liver Frailty Index), the collection of interrelated events and the reassessment of hepatic disease as well as the re-evaluation of the nutritional strategy (CNO, enteral or parenteral nutrition)
- No dietary management — OTHERThe patient will be followed up by his reference hepatologist every 3 months. Follow-up visits at 3 months and 6 months waiting for liver transplantation will be performed by Clinical Research assistant on the same day as the follow-up consultation with his hepatologist with the completion of the Liver Frailty Index test and the collection of intercurrent events and the reassessment of liver disease.
Study Details
Cirrhosis is a major public health issue responsible for about 15000 deaths each year. Liver transplantation (LT) remains the only curative treatment for decompensated cirrhosis. Decompensated cirrhotic patients awaiting LT are malnourished, sarcopenic and fragile. The evaluation of the nutritional status of these patients is complex because the anthropometric data that define undernutrition (weight variation, BMI) are often compromised by the presence of edema and ascites related to liver disease. It therefore seems appropriate to focus on the fragility and sarcopenia of the cirrhotic patient as a reflection of the nutritional status. In 2017, the American team of Lai et al. validated a Liver fraily index (LFI) score of frailty specific to cirrhotic patients waiting for LT. The LFI is composed of three simple physical tests (Grip test, chair lift test, and balance tests) performed at the patient's bedside, which results in a quantitative and reproducible frailty score. Frailty while waiting for LT is associated with an increase in mortality on the waiting list, independently of the MELD (Model for End stage Liver disease) score, which is a reflection of liver severity. About half of the patients who are candidates for LT will present an aggravation of their frailty while waiting for LT. To date, no study has reported the results of a nutritional intervention on the evolution of fragility in patients awaiting LT. The objective of our study is to evaluate the impact of a nutritional management and follow-up by a dietitian specialized in hepatology on the fragility of patients waiting for LT. This is a monocentric study, randomized in two parallel groups (an intervention group with nutritional follow-ups by a trained dietitian and a control group with follow-up by the reference hepatologist without specific dietary management by a dietician) in open. All patients enrolled on the LT list with an LFI \> 3.2 (pre-frail and frail state) will be included in the study. It is planned to include 210 patients over a period of 24 months. The LFI will be measured for all patients (control group + intervention group) at 3 and 6 months, as part of their follow-up in the LT center. This study will also make it possible to correlate frailty with other parameters (severity of liver disease, access to LT).
Key Dates
- First listed
- Apr 4, 2025
- Start date
- Jun 30, 2025
- Status verified
- Jul 2025
- Primary completion
- Jun 30, 2027
- Completion
- Dec 30, 2027
Study Design
- Enrollment
- 210 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Dietary intervention GroupThe intervention consists of a personalized dietary management with a nutritional follow-up pending transplantation. Teleconsultation appointments are scheduled with the dietician for dietary coaching and a re-evaluation of the nutritional strategy. Follow-up visits in person, carried out by the dietician at the 3rd and 6th month waiting for liver transplantation and are coupled with the usual consultations with the referring hepatologist. The visits allow the realization of LFI (Liver Frailty Index), the collection of interrelated events and the reassessment of hepatic disease as well as the re-evaluation of the nutritional strategy (oral nutritional supplement, enteral or parenteral nutrition)
- Other: Standard Follow upThe patient will be followed up by his referee hepatologist every 3 months. The 3-month and 6-month follow-up visits pending transplantation will be performed with a Clinical Research Assistant on the same day as the follow-up consultation with his hepatologist with the completion of the LFI test and the collection of intercurrent events and the re-evaluation of the liver disease.
Primary Outcome Measure
Evaluate the impact at 3 months, of a nutritional management and follow-up by a dietitian specialized in hepatology compared to the usual management without dietary follow-up, on the fragility of patients waiting for liver transplantation (LT). [ Time Frame: 3rd month after visit 1. ]
Central Contacts
- Maxime PATUREL, Diététicien, FF CDS+33 (0)4 72 07 25 43
- Mahutondji Calèbe SOMASSE+33 (0)4 72 07 13 36
Related Studies
- Blood Collection Biorepository for Liver Disease ResearchRecruiting · State University of New York at Buffalo · Buffalo, New York
- Mechanisms of Malnutrition in Cirrhosis With Portosystemic ShuntingRecruiting · The Cleveland Clinic · Cleveland, Ohio
- Novel Tracer Methods to Evaluate Muscle Protein Metabolism in CirrhosisRecruiting · The Cleveland Clinic · Cleveland, Ohio
- Safety and Efficacy of Atorvastatin v. Placebo on HCC RiskPHASE2 · Recruiting · Raymond Chung · Boston, Massachusetts